The Management of Primary Carcinoma of The Urethra - Reza Mehrazin

July 18, 2021

In a presentation, followed by an educational discussion, from Reza Mehrazin, MD, the topic of management of primary urothelial carcinoma is discussed in depth. Dr. Mehrazin began his presentation with epidemiology and risk factors for this aggressive disease. He discussed the risk factor of advanced age (>60 years old) along with other less-known risk factors, such as chronic urethral irritation. Primary urethral carcinoma gender-influenced outcomes are discussed on the basis of anatomy and physiology, and the respective differences between each gender. Dr. Mehrazin discusses how even though females are less likely to develop primary urethral carcinomas, they can still show up in very aggressive forms. While treatment, usually as upfront systemic therapy, is a large piece of the puzzle, imaging (MRI and CT scans) and early detection are keys in the management of this cancer. When asked about patient follow-up, Dr. Mehrazin discusses his more - intense form of follow-up with annual urethroscopies to monitor symptoms. In his closing statement, Dr. Mehrazin discussed the lower prevalence of this cancer but warned of its highly aggressive nature.  

Biographies:

Reza Mehrazin, MD, Associate Professor of Urology, The Mount Sinai Hospital

Ashish Kamat, MD, MBBS, Professor, Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, President, International Bladder Cancer Group (IBCG), Houston, Texas


Read the Full Video Transcript